Publication Date:
2014-07-22
Description:
Inflammation in HIV infection is predictive of non-AIDS morbidity and death, higher set point plasma virus load and virus acquisition; thus, therapeutic agents are in development to reduce its causes and consequences. However, inflammation may simultaneously confer both detrimental and beneficial effects. This dichotomy is particularly applicable to type I interferons (IFN-I) which, while contributing to innate control of infection, also provide target cells for the virus during acute infection, impair CD4 T-cell recovery, and are associated with disease progression. Here we manipulated IFN-I signalling in rhesus macaques (Macaca mulatta) during simian immunodeficiency virus (SIV) transmission and acute infection with two complementary in vivo interventions. We show that blockade of the IFN-I receptor caused reduced antiviral gene expression, increased SIV reservoir size and accelerated CD4 T-cell depletion with progression to AIDS despite decreased T-cell activation. In contrast, IFN-alpha2a administration initially upregulated expression of antiviral genes and prevented systemic infection. However, continued IFN-alpha2a treatment induced IFN-I desensitization and decreased antiviral gene expression, enabling infection with increased SIV reservoir size and accelerated CD4 T-cell loss. Thus, the timing of IFN-induced innate responses in acute SIV infection profoundly affects overall disease course and outweighs the detrimental consequences of increased immune activation. Yet, the clinical consequences of manipulation of IFN signalling are difficult to predict in vivo and therapeutic interventions in human studies should be approached with caution.〈br /〉〈br /〉〈a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4418221/" target="_blank"〉〈img src="https://static.pubmed.gov/portal/portal3rc.fcgi/4089621/img/3977009" border="0"〉〈/a〉 〈a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4418221/" target="_blank"〉This paper as free author manuscript - peer-reviewed and accepted for publication〈/a〉〈br /〉〈br /〉〈span class="detail_caption"〉Notes: 〈/span〉Sandler, Netanya G -- Bosinger, Steven E -- Estes, Jacob D -- Zhu, Richard T R -- Tharp, Gregory K -- Boritz, Eli -- Levin, Doron -- Wijeyesinghe, Sathi -- Makamdop, Krystelle Nganou -- del Prete, Gregory Q -- Hill, Brenna J -- Timmer, J Katherina -- Reiss, Emma -- Yarden, Ganit -- Darko, Samuel -- Contijoch, Eduardo -- Todd, John Paul -- Silvestri, Guido -- Nason, Martha -- Norgren, Robert B Jr -- Keele, Brandon F -- Rao, Srinivas -- Langer, Jerome A -- Lifson, Jeffrey D -- Schreiber, Gideon -- Douek, Daniel C -- AI-076174/AI/NIAID NIH HHS/ -- HHSN261200800001E/PHS HHS/ -- P51 OD011132/OD/NIH HHS/ -- R24 RR017444/RR/NCRR NIH HHS/ -- ZIA AI005034-13/Intramural NIH HHS/ -- England -- Nature. 2014 Jul 31;511(7511):601-5. doi: 10.1038/nature13554. Epub 2014 Jul 9.〈br /〉〈span class="detail_caption"〉Author address: 〈/span〉1] Human Immunology Section, Vaccine Research Center, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, Maryland 20892, USA [2] Division of Infectious Diseases, Department of Internal Medicine, University of Texas Medical Branch at Galveston, Galveston, Texas 77555, USA. ; 1] Division of Microbiology and Immunology, Emory Vaccine Center, Yerkes National Primate Research Center, Atlanta, Georgia 30322, USA [2] Non-Human Primate Genomics Core, Yerkes National Primate Research Center, Robert W. Woodruff Health Sciences Center, Emory University, Atlanta, Georgia 30322, USA. ; AIDS and Cancer Virus Program, Leidos Biomedical Research, Inc., Frederick National Laboratory, Frederick, Maryland 21702, USA. ; Human Immunology Section, Vaccine Research Center, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, Maryland 20892, USA. ; Department of Biological Chemistry, Weizmann Institute of Science, Rehovot 76100, Israel. ; Laboratory of Animal Medicine, Vaccine Research Center, National Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, Maryland 20892, USA. ; Division of Microbiology and Immunology, Emory Vaccine Center, Yerkes National Primate Research Center, Atlanta, Georgia 30322, USA. ; Biostatistics Research Branch, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA. ; Department of Genetics, Cell Biology and Anatomy, University of Nebraska Medical Center, Omaha, Nebraska 68198, USA. ; Department of Pharmacology, Rutgers - Robert Wood Johnson Medical School, Piscataway, New Jersey 08854, USA.〈br /〉〈span class="detail_caption"〉Record origin:〈/span〉 〈a href="http://www.ncbi.nlm.nih.gov/pubmed/25043006" target="_blank"〉PubMed〈/a〉
Keywords:
Animals
;
Antiviral Agents/pharmacology/therapeutic use
;
CD4-Positive T-Lymphocytes/drug effects/immunology
;
*Disease Progression
;
Gene Expression Regulation/drug effects
;
Immunity, Innate/drug effects
;
Interferon-alpha/pharmacology/*therapeutic use
;
Kaplan-Meier Estimate
;
Macaca mulatta/*immunology
;
Signal Transduction/drug effects
;
*Simian Acquired Immunodeficiency Syndrome/drug therapy/immunology/prevention &
;
control
;
Simian Immunodeficiency Virus/*immunology
Print ISSN:
0028-0836
Electronic ISSN:
1476-4687
Topics:
Biology
,
Chemistry and Pharmacology
,
Medicine
,
Natural Sciences in General
,
Physics
Permalink
